Source article originally published on
Article Summary and/or Excerpt:
“Atomic AI” is a startup that uses artificial intelligence to design new RNA molecules for a variety of medical applications. The company’s technology is based on a marriage of AI and biology, and it aims to make RNA-based therapies more efficient and effective. According to the company, its AI-designed RNA molecules can be used to target specific cells, tissues, or organs in the body, which could have a wide range of therapeutic applications. The company is also exploring the use of its technology in the development of new diagnostic tools. Atomic AI has raised $6 million in seed funding to support its research and development efforts.
One of the main advantages of Atomic AI’s technology is that it can generate a large number of RNA molecules quickly and efficiently. This allows the company to screen a large number of potential therapeutic candidates in a relatively short period of time. Additionally, the company’s AI-based design process is able to identify molecules that might not be found through traditional methods, which could lead to the development of new and innovative therapies. The company plans to use the funding to continue to develop and refine its technology, as well as to form partnerships with pharmaceutical and biotech companies to bring its RNA-based therapies to market.